Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.
CancerNetwork® spoke with Tiffany Sia, MD, a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center in New York, during the 2022 Annual Global Meeting of the International Gynecologic Cancer Society about different procedural interventions used across 887 patients with gynecologic malignancies who experienced oligoprogression during treatment with immune checkpoint inhibitors (ICI) at her institution. In a chart review, interventions included either surgical resection (n = 10), interval radiation (IR) ablation (n = 3), or radiation therapy (n = 28) in 41 total patients who received ICI and had oligoprogressive disease. These types of interventions appeared to benefit this patient subset and offers evidence for working them into treatment for better survival outcomes.
What we found is that the patients who were treated with either surgical procedures, radiation therapies, or IR-guided ablations had very favorable outcomes overall. We would recommend that we can continue to treat these patients with oligoprogression with combined modalities of immune checkpoint blockade and consider these procedural interventions for localized oligoprogression.
The take-home point is that this is feasible and the patients overall have good outcomes. We should not rule out the possibility of an interventional procedure just because a patient is on immune checkpoint blockade; it is doable. This is an ongoing field of study. The number of patients in our cohort is relatively small, but as more and more patients being treated with these types of drugs and seeing responses, we might have more patients with oligoprogression. This is going to be an interesting question moving forward.
Sia T, Wan V, Zivanovec O, et al. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies. Presented at the Annual Global Meeting of the International Gynecologic Cancer Society; New York, NY; September 29-October 1, 2022. Poster FP014.